Épidémiologie et pathogenèse de l’HS
Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996;35:191–4.
Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012;366:158-64.
Jemec GB, Kimball AB. Hidradenitis suppurativa: Epidemiology and scope of the problem. J Am Acad Dermatol 2015;73(5 Suppl 1):S4–7
Revuz JE, Canoui-Poitrine F, Wolkenstein P et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008;59:596–601.
Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009;23:985–98.
von Laffert M, Helmbold P, Wohlrab J et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010;19:533–7.
Épidémiologie de l’HS
Deckers IE, van der Zee HH, Boer J et al. Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. J Am Acad Dermatol 2015;72:485–8.
Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996;35:191–4.
Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012;366:158-64. Jemec GB, Kimball AB. Hidradenitis suppurativa: Epidemiology and scope of the problem. J Am Acad Dermatol 2015;73(5 Suppl 1):S4–7.
Margesson LJ, Danby FW. Hidradenitis suppurativa. Best Pract Res Clin Obstet Gynaecol 2014;28:1013–27.
Revuz JE, Canoui-Poitrine F, Wolkenstein P et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008;59:596–601.
Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009;23:985–98.
Schrader AM, Deckers IE, van der Zee HH et al. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol 2014;71:460–7.
von Laffert M, Stadie V, Wohlrab J et al. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol 2011;164:367–71.
Yu C, Cook M. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990;122:763–9.
Zouboulis CC, Del Marmol V, Mrowietz U et al. Hidradenitis suppurativa/acne inversa: Criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 2015b;231:184–90.
Zouboulis CC, Desai N, Emtestam L et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015a;29:619–44.
Pronostic et évolution clinique de l’HS
Canoui-Poitrine F, Revuz JE, Wolkenstein P et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009; 61: 51–57.
Kromann CB, Deckers IE, Esmann S et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol 2014;171:819–24.
Schrader AM, Deckers IE, van der Zee HH et al. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol 2014;71:460–7.
Pathogenèse de l’HS
1. L’essentiel de la peau : anatomie et physiologie
Murphy K. Basic concepts in immunology. In: Janeway’s Immunology, 8th ed. New York, NY: Garland Science, 2012:1–36.
Norris DA. Structure and function of the skin. In: Goldman L, Schafer AI (Eds.). Goldman’s
Cecil Medicine, 24th ed. Philadelphia, PA: Saunders/Elsevier Inc.,2012:2496–03.
van der Zee HH, de Ruiter L, van den Broecke DG et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011;164:1292–8.
Weller R, Hunter J, Savin J et al. The function and structure of the skin. In: Sugden M,
Blundell R (eds.) Clinical Dermatology, 4th ed. Malden, MA: Blackwell Publishing, Inc., 2008:10–33.
2. Processus pathogénique de l’HS
Kelly G, Sweeney CM, Tobin AM et al. Hidradenitis suppurativa: the role of immune dysregulation. Int J Dermatol 2014;53:1186–96.
Kelly G, Hughes R, McGarry T et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol 2015;173:1431–9.
Kelly G, Prens EP. Inflammatory mechanisms in hidradenitis suppurativa. Dermatol Clin 2016;34:5158.
Nazary M, van der Zee HH, Prens EP et al. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. Eur J Pharmacol 2011;672:1–8.
Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009;23:985–98. Schlapbach C, Hänni T, Yawalkar N et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011;65:790–8.
van der Zee HH, Laman JD, de Ruiter L et al. Adalimumab (antitumour necrosis factor-alpha) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol 2012;166:298–305.
van der Zee HH, Laman JD, Boer J et al. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol 2012;21:735–9.
Histologie de l’HS
Collier F, Smith RC, Morton CA. Diagnosis and management of hidradenitis suppurativa. BMJ 2013;346:f2121.
Emelianov VU, Bechara FG, Glaser R et al. Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa. Br J Dermatol 2012;166:1023–34.
Jemec GB, Hansen U. Histology of hidradenitis suppurativa. J Am Acad Dermatol 1996;34:994–9.
Kamp S, Fiehn AM, Stenderup K et al. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br J Dermatol 2011;164:1017–22.
Kurokawa I, Nishijima S, Kusumoto K et al. Immunohistochemical study of cytokeratins in hidradenitis suppurativa (acne inversa). J Int Med Res 2002;30:131–6.
Nazary M, van der Zee HH, Prens EP et al. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. Eur J Pharmacol 2011;672:1–8.
van der Zee HH, de Ruiter L, van den Broecke DG et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011;164:1292–8.
von Laffert M, Helmbold P, Wohlrab J et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010;19:533–7.
von Laffert M, Stadie V, Wohlrab J et al. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol 2011;164:367–371.
Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990;122:763–9.
Zouboulis CC, Desai N, Emtestam L et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015a;29:619–44.